Table 5.
Doxorubicin-induced cardiotoxicity parameters of different formulations after 2 weeks of final dosing
| Treatment group | Serum CK-MB (U/L)* | LDH (IU/L)* | % SOD* | Heart weight (g)* |
|---|---|---|---|---|
| Control (without any drug treatment) | 44.44±3.1 | 142.32±8.12 | 100±7.3 | 0.1722±0.03 |
| BL-NP | 55.54±4.4 | 149.0±8.5 | 98.65±7.0 | 0.1662±0.022 |
| Free-DOX | 126.65±7.0a,b | 250.10±11.7a,b | 34.02±4.5a,b | 0.1420±0.025 |
| DOX-NP | 70.20±5.6a,b,c | 180.39±9.23a,b,c | 42.78±5.1a,b | 0.1650±0.019 |
| DOX-Ab-NP | 66.63±6.1a,b,c | 166.67±8.8c | 49.22±5.5a,b | 0. 1670±0.036 |
Notes: *Data show mean ± SD (n=3). Significant difference corresponding from control ap<0.05, BL-NP; bp<0.05, Free-DOX; cp<0.05.
Abbreviations: CK-MB, creatine phosphokinase; LDH, lactate dehydrogenase; SOD, superoxide dismutase; BL-NP, blank nanoparticles; DOX, doxorubicin; DOX-NP, doxorubicin-loaded nanoparticles; DOX-Ab-NP, doxorubicin loaded antibody-conjugated nanoparticles.